{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:01:00Z","timestamp":1790949660922,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE AND OBJECTIVES:<\/jats:title>\n            <jats:p>This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>A retrospective analysis of data from the phase III CONFIRM study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PARTICIPANTS:<\/jats:title>\n            <jats:p>Adult patients with HRS-AKI admitted to the ICU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>In this substudy, we evaluated outcomes of the ICU stay and the need for organ support, including renal replacement therapy (RRT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Among 300 patients with HRS-AKI from the CONFIRM study, 45 were treated in the ICU (terlipressin, 31\/199 [16%]; placebo, 14\/101 [14%]). On ICU admission, baseline demographics were similar across treatment arms, including severity of liver dysfunction. Among patients alive at the end of the ICU stay, those randomized to terlipressin had a significantly shorter median length of ICU stay than placebo (4 vs 11 d; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). Terlipressin-treated patients had a significantly larger improvement in renal function from baseline versus placebo (\u20130.7 vs +0.2\u2009mg\/dL; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.001), including when accounting for the interaction between treatment and day-of-patient-admission to the ICU (\u20130.7 vs +0.9\u2009mg\/dL; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.001). Cumulative requirement for RRT through day 90 was improved in the terlipressin arm versus placebo (10\/31 [32%] vs 8\/14 [57%]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.12), although not significantly. Of 13 patients who received a liver transplant, five out of five (100%) in the placebo arm needed RRT through day 90 versus five out of eight (63%) in the terlipressin arm.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>In this subanalysis of CONFIRM, patients admitted to the ICU with HRS-AKI who received terlipressin were more likely to achieve renal function improvement, based on serum creatinine changes by the end of treatment, and had significantly shorter lengths of ICU stay than patients randomized to the placebo arm.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000890","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:21:33Z","timestamp":1680049293000},"page":"e0890","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Role of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Admitted to the ICU: A Substudy of the CONFIRM Trial"],"prefix":"10.1097","volume":"5","author":[{"given":"Constantine J.","family":"Karvellas","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine and Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Departments of Critical Care Medicine and Hepatology, Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody C.","family":"Olson","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Surgery, University of Kansas Medical Center, Kansas City, KS."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram","family":"Jamil","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Hampton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2014-308874","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites.","volume":"64","author":"Angeli","year":"2015","journal-title":"Gut"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"100270","DOI":"10.1016\/j.aohep.2020.09.014","article-title":"Renal and brain failure predict mortality of patients with acute-on-chronic liver failure admitted to the intensive care unit.","volume":"22","author":"Mendez-Guerrero","year":"2021","journal-title":"Ann Hepatol"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2017.07.008","article-title":"Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.","volume":"67","author":"Piano","year":"2017","journal-title":"J Hepatol"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.14309\/ajg.0000000000000771","article-title":"The use of NACSELD and EASL-CLIF classification systems of ACLF in the prediction of prognosis in hospitalized patients with cirrhosis.","volume":"115","author":"Cao","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2019.07.002","article-title":"News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.","volume":"71","author":"Angeli","year":"2019","journal-title":"J Hepatol"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases.","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S2468-1253(16)30157-1","article-title":"Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: A systematic review and network meta-analysis.","volume":"2","author":"Facciorusso","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S146034","article-title":"In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2.","volume":"10","author":"Jamil","year":"2018","journal-title":"J Exp Pharmacol"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00365520310008728","article-title":"Effect of terlipressin on blood volume distribution in patients with cirrhosis.","volume":"39","author":"Kiszka-Kanowitz","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome.","volume":"4","author":"Gines","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1.","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome.","volume":"384","author":"Wong","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2014.06.012","article-title":"Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.","volume":"61","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/CCM.0000000000005595","article-title":"The comparative effectiveness of vasoactive treatments for hepatorenal syndrome: A systematic review and network meta-analysis.","volume":"50","author":"Pitre","year":"2022","journal-title":"Crit Care Med"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1590\/S0004-28032016000200014","article-title":"Economic evaluation under the perspective of the Brazilian Public Health System.","volume":"53","author":"Mattos","year":"2016","journal-title":"Arq Gastroenterol"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure.","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/liv.14703","article-title":"Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives.","volume":"40","author":"Kulkarni","year":"2020","journal-title":"Liver Int"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.phrs.2016.08.027","article-title":"Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile.","volume":"113","author":"Colson","year":"2016","journal-title":"Pharmacol Res"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2021.08.016","article-title":"Terlipressin and the treatment of hepatorenal syndrome: How the CONFIRM trial moves the story forward.","volume":"79","author":"Belcher","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"e0431","DOI":"10.1097\/MD.0000000000010431","article-title":"Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R25-20240807","first-page":"CD011532","article-title":"Terlipressin versus other vasoactive drugs for hepatorenal syndrome.","volume":"9","author":"Israelsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1111\/ajt.13790","article-title":"Protecting the kidney in liver transplant candidates: Practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice.","volume":"16","author":"O\u2019Leary","year":"2016","journal-title":"Am J Transplant"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/liv.15367","article-title":"Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.","volume":"42","author":"Allegretti","year":"2022","journal-title":"Liver Int"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamainternmed.2015.0372","article-title":"Variability among US intensive care units in managing the care of patients admitted with preexisting limits on life-sustaining therapies.","volume":"175","author":"Hart","year":"2015","journal-title":"JAMA Intern Med"}],"updated-by":[{"DOI":"10.1097\/cce.0000000000001080","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000}}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:04:00Z","timestamp":1723028640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000890","relation":{"correction":[{"id-type":"doi","id":"10.1097\/CCE.0000000000001080","asserted-by":"object"}]},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}